Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar - 2Chinese mega embassy could bring security advantages, says No 10
- 37 Strange Apparatuses to Make Your Party Stick Out!
- 4Palestinians tell BBC they were sexually abused in Israeli prisons
- 5The Best Games Crossroads in History
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- One-third of asylum applications by Iranians approved in Germany
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- 'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
